Newsletter
28 de October de 2014
Newsletter 2014.07 – ANVISA publishes resolutions on new procedures relative to marketing authorization in Brazil: RDC #58 and #60/2014
The main law regulating the health system in Brazil – Law #6,360 dated 1976 – establishes that each and every drug available in the pharmaceutical market must be approved by the Ministry of Health. Since the creation of the Brazilian FDA (called ANVISA), this autonomous autarchy subordinated to the Ministry of Health is in charge of issuing marketing authorization for drugs for human use and of establishing specific resolutions in order to regulate each of the existing categories of medicaments, such as the new drugs, generics, similars, biologicals.
According to ANVISA’s requirements, the documentation submitted by the manufacturers of both generic and similar drugs, upon applying for marketing approval, is significantly simplified compared to the reference product (the so-called “abridged process”), as only pharmaceutical equivalence and relative bioavailability/ bioequivalence assays are required to obtain approval for products pertaining to these categories.
It should be noted that, since the publication of Resolutions RDC #133 (new applications for marketing approval) and RDC #134 (similars, already approved), both dated May 29, 2003, ANVISA has begun to require proof of therapeutic equivalence also for similar drugs; therefore, it is estimated that all manufacturers of these products will have complied with such requirement by the end of 2014.
Accordingly, studies of pharmaceutical equivalence and bioavailability/bioequivalence became necessary in order to obtain marketing authorization for both generic and similar drugs, although the latter were not then yet considered to be interchangeable with the reference product.
Last related news
19 de September de 2025
Transition to Regulatory Agency and New Responsibilities under the Digital Child and Adolescent Statute
The past few days have brought significant developments for the National Data Protection Agency (“ANPD”). Firstly, Provisional Measure No. 1,317/2025 was published … Transition to Regulatory Agency and New Responsibilities under the Digital Child and Adolescent Statute
27 de August de 2025
Temporary Use of Unlicensed Software: Legal Liability Regardless of Duration
Companies often argue, during audits, that the use of unlicensed software occurred only briefly—over a few days or weeks—as a way to … Temporary Use of Unlicensed Software: Legal Liability Regardless of Duration
22 de August de 2025
Update from Brazil: The Debate on Platform Monetization and Accountability
A significant debate has recently emerged in Brazil following an episode involving the creator Felca. The controversy centered on the adultization of … Update from Brazil: The Debate on Platform Monetization and Accountability